| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0140-6736(93)92187-X |
| P698 | PubMed publication ID | 7901531 |
| P2093 | author name string | T Ohno | |
| J Y Lau | |||
| G L Davis | |||
| M Mizokami | |||
| D A Diamond | |||
| J Kniffen | |||
| P433 | issue | 8881 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic hepatitis | Q62019625 |
| P304 | page(s) | 1208-1209 | |
| P577 | publication date | 1993-11-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. | |
| P478 | volume | 342 |
| Q59388270 | A comparison of four types of interferon alpha in the treatment of chronic hepatitis C |
| Q43795947 | Biochemical response to interferon therapy correlates with interferon sensitivity‐determining region in hepatitis C virus genotype 1b infection |
| Q42980301 | Changes in hepatitis C virus quasispecies and density populations in patients before and after interferon therapy |
| Q40461196 | Chronic viral hepatitis and the management of chronic renal failure |
| Q35960902 | Clinical application of hepatitis C virus genotyping and quantitation |
| Q44482188 | Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay |
| Q43034283 | Clinical significance of elevated serum interferon- inducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels |
| Q43034948 | Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viraemia and histologic activity |
| Q36732386 | Cumulative risk of hepatocellular carcinoma in hepatitis C virus carriers: statistical estimations from cross-sectional data |
| Q42989422 | Detection of widespread hepatocyte infection in chronic hepatitis C |
| Q42986936 | Determination of HCV RNA concentration by direct quantitation of the products from a single RT-PCR. |
| Q42999898 | Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta |
| Q34210742 | Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma |
| Q42989435 | Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus |
| Q33809548 | Effects of interferon therapy in "non responder" patients with chronic hepatitis C. |
| Q45783851 | Efficacy of an analysis of lymphocyte subsets in predicting the clinical response to alpha-interferon therapy in thalassaemia patients with chronic infection by hepatitis C virus: a pilot study |
| Q47830400 | Efficacy of different schedules in the management of chronic hepatitis C with interferon-oc |
| Q43031055 | Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone |
| Q42631714 | Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection |
| Q43035052 | Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. |
| Q71732644 | Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver |
| Q42978693 | Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection |
| Q33945424 | Gary L. Davis, MD: a conversation with the editor. Interview by William Clifford Roberts |
| Q74751759 | Hepatitis C |
| Q42988161 | Hepatitis C Viral RNA Status at Two Weeks of Therapy Predicts the Eventual Response |
| Q43035045 | Hepatitis C virus RNA and long-term response to recombinant interferon-alpha 2b in patients with chronic hepatitis C. |
| Q41225114 | Hepatitis C virus infection: clinical aspects and treatment with interferon alfa |
| Q71702111 | Hepatitis C: diagnosis and treatment |
| Q36642065 | Hepatitis C: progress and problems |
| Q41574253 | Histopathology and detection of hepatitis C virus in liver |
| Q42981208 | Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus |
| Q74351860 | Interferon induces insulin resistance in patients with chronic active hepatitis C |
| Q40707634 | Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy |
| Q40399739 | Interferons for viral hepatitis |
| Q44210299 | Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? |
| Q45195135 | Lack of association between occult hepatitis B virus DNA viral load and aminotransferase levels in patients with hepatitis C virus-related chronic liver disease |
| Q73562590 | Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis |
| Q42991587 | Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment. |
| Q43038103 | Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C |
| Q34798261 | Lymphoblastoid interferon alfa treatment in chronic hepatitis C |
| Q58622883 | Management of hepatitis C |
| Q43030170 | Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response |
| Q40442669 | Pathology of hepatitis C virus infection |
| Q27478466 | Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules |
| Q27485655 | Preclinical evaluation of AMPLICOR hepatitis C virus test for detection of hepatitis C virus RNA |
| Q43041709 | Prediction of response to interferon treatment of chronic hepatitis C. |
| Q42977228 | Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio |
| Q42993182 | Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. |
| Q42984115 | Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study. |
| Q33931554 | Quantitative molecular analysis of virus expression and replication. |
| Q40374984 | Quantitative molecular methods in virology |
| Q42994815 | Selection of genetic variants of the 5' noncoding region of hepatitis C virus occurs only in patients responding to interferon alpha therapy |
| Q42990986 | Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification |
| Q41601983 | Should we test hepatitis C virus genotype and viraemia level in patients with chronic hepatitis C? |
| Q73629646 | Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy |
| Q43000130 | Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study |
| Q30431132 | The Biology of Interferon-α and the Clinical Significance of Anti-Interferon Antibodies |
| Q40957762 | The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review |
| Q58803510 | Transfusion-associated chronic hepatitis C: Alpha-n1 interferon for 6 vs. 12 months |
| Q45886295 | Treatment of hepatitis C infection in haemophiliacs: the Edinburgh experience. |
| Q73548999 | Treatments of hepatitis C |
| Q43047084 | Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices |
Search more.